In this issue of Biotech Frontiers, we’ll lay out why one doctor’s five decades of pioneering work in oncology has not been simply an academic exercise… but instead stands to transform the lives of many cancer patients and reward this company’s shareholders who have funded its development.
Dear Porter & Co. Biotech Frontiers Subscribers: One of the defining aspects of biotech is that it’s a catalyst-driven investment domain. This means that the fate of biotech investments often depends on specific, concrete events – such as clinical-trial-data releases or regulatory decisions. These decisions can drive biotech stocks much higher… or much lower. This
Dear Porter & Co. Biotech Frontiers Subscribers: On January 22, Sagimet Biosciences (Nasdaq: SGMT) – a member of our inaugural 10-stock basket kicking off our portfolio – announced top-line results from the Phase 2b clinical trial of its lead drug candidate, Denifanstat. Denifanstat is a promising treatment for liver fibrosis and NASH, serious metabolic illnesses that afflict
We’re in the midst of the longest and most punishing bear market in the history of biotech. Investors are so repelled by the sector that they’re ascribing negative value to many of its companies, creating the perfect opportunity for biotech investors. That’s why in this launch issue of Biotech Frontiers, we are recommending a basket of 10 biotech stocks to buy immediately.
